In this episode, I’ll discuss the impact of ceftriaxone on the development of pneumonia and noninfectious outcomes after out-of-hospital cardiac arrest.
While previous studies have shown that ceftriaxone can prevent pneumonia after out-of-hospital cardiac arrest (OHCA), the effects on other outcomes, such as mortality and the development of resistance, are not as certain.
A group of authors published in the journal Chest a randomized controlled trial to determine whether prophylactic ceftriaxone reduces the incidence of early-onset pneumonia without increasing the acquisition of antibiotic resistance genes after OHCA.
Although over 400 patients were screened, only 53 were randomized to receive ceftriaxone 2 g or matching placebo every 12 hours for 3 days. As one patient dropped out, there were 26 in each group in the final analysis.
While early-onset pneumonia was numerically less frequent in the ceftriaxone group at 10 patients compared to 18 with placebo, this difference barely missed statistical significance. The risk ratio for pneumonia was 0.57 but the upper limit of the 95% confidence interval was 1.001.
Significantly fewer patients in the ceftriaxone group required additional open-label broad-spectrum antibiotics, with a risk ratio of 0.64 and a 95% confidence interval that did not exceed 0.94.
After adjustment for differences in the presence of antibiotic resistance genes prior to study drug administration, patients in the ceftriaxone group acquired significantly fewer antibiotic resistance genes when compared with the placebo group with an incidence risk ratio of 0.3.
The authors concluded:
This trial was inconclusive regarding the impact of ceftriaxone prophylaxis on reducing the incidence of early-onset pneumonia following OHCA. However, ceftriaxone was associated with less frequent administration of open-label antibiotics and reduced acquisition of antibiotic resistance genes to frequently used antibiotics in the ICU.
Even though the study was small and inclusive about the effect of ceftriaxone in preventing pneumonia, the statistically significant findings on antibiotic resistance and reduced use of broad-spectrum antibiotics suggest that short-course prophylaxis may still offer clinical benefits for antimicrobial stewardship and patient safety.
To access my free download area with 20 different resources to help you in your practice, go to pharmacyjoe.com/free.
If you like this post, check out my book – A Pharmacist’s Guide to Inpatient Medical Emergencies: How to respond to code blue, rapid response calls, and other medical emergencies.
Leave a Reply